Your browser doesn't support javascript.
loading
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy, Alexandra; Tovar Sanchez, Tamara; Kouanfack, Charles; Mpoudi-Etame, Mireille; Leroy, Sandrine; Perrineau, Ségolène; Lantche Wandji, Martial; Tetsa Tata, Darius; Omgba Bassega, Pierette; Abong Bwenda, Thérèse; Varloteaux, Marie; Tongo, Marcel; Mpoudi-Ngolé, Eitel; Montoyo, Alice; Mercier, Noémie; LeMoing, Vincent; Peeters, Martine; Reynes, Jacques; Delaporte, Eric.
Afiliação
  • Calmy A; Division of Infectious Diseases, HIV-AIDS Unit, Geneva University Hospitals, Geneva, Switzerland. Electronic address: alexandra.calmy@hcuge.ch.
  • Tovar Sanchez T; TransVIHMI, University of Montpellier, IRD, INSERM, 34394 Montpellier, France.
  • Kouanfack C; Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon; Day Stay Hospital, Central Hospital of Yaoundé, Henri-Dunant, Yaoundé, Cameroon; ANRS Cameroon site, Central Hospital of Yaoundé, Henri-Dunant, Yaoundé, Cameroon.
  • Mpoudi-Etame M; Regional Military Hospital Number 1, Yaoundé, Cameroon.
  • Leroy S; TransVIHMI, University of Montpellier, IRD, INSERM, 34394 Montpellier, France.
  • Perrineau S; TransVIHMI, University of Montpellier, IRD, INSERM, 34394 Montpellier, France.
  • Lantche Wandji M; ANRS Cameroon site, Central Hospital of Yaoundé, Henri-Dunant, Yaoundé, Cameroon.
  • Tetsa Tata D; ANRS Cameroon site, Central Hospital of Yaoundé, Henri-Dunant, Yaoundé, Cameroon.
  • Omgba Bassega P; Cité Verte District Hospital, Cité Verte District, Yaoundé, Cameroon.
  • Abong Bwenda T; ANRS Cameroon site, Central Hospital of Yaoundé, Henri-Dunant, Yaoundé, Cameroon.
  • Varloteaux M; ANRS Cameroon site, Central Hospital of Yaoundé, Henri-Dunant, Yaoundé, Cameroon.
  • Tongo M; Emerging and Re-emerging Diseases Research Centre, IMPM, Sise à Ngoa-Ekelle, Yaoundé, Cameroon.
  • Mpoudi-Ngolé E; Emerging and Re-emerging Diseases Research Centre, IMPM, Sise à Ngoa-Ekelle, Yaoundé, Cameroon.
  • Montoyo A; Office of International Research and Collaboration, ANRS Inserm, Paris, France.
  • Mercier N; Office of Clinical Trial Safety, ANRS Inserm, Paris, France.
  • LeMoing V; TransVIHMI, University of Montpellier, IRD, INSERM, 34394 Montpellier, France; Montpellier University Hospital Centre, Montpellier, France.
  • Peeters M; TransVIHMI, University of Montpellier, IRD, INSERM, 34394 Montpellier, France.
  • Reynes J; TransVIHMI, University of Montpellier, IRD, INSERM, 34394 Montpellier, France; Montpellier University Hospital Centre, Montpellier, France.
  • Delaporte E; TransVIHMI, University of Montpellier, IRD, INSERM, 34394 Montpellier, France; Montpellier University Hospital Centre, Montpellier, France.
Lancet HIV ; 7(10): e677-e687, 2020 10.
Article em En | MEDLINE | ID: mdl-33010241
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Terapia Antirretroviral de Alta Atividade Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: Lancet HIV Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Terapia Antirretroviral de Alta Atividade Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: Lancet HIV Ano de publicação: 2020 Tipo de documento: Article